belantamab mafodotin

GlaxoSmithKline plc (NYSE: GSK) announced Wednesday the United States Food and Drug Administration had approved its cancer drug aimed at treating refractory multiple myeloma in adults. What Happened The monotherapy, belantamab mafodotin, or BLENREP, stands approved for those patients who have...